Cost associated with venous thromboembolism treatment in the community

References

• Rosendaal FR. Risk factors for venous thrombotic disease. Thrombosis and Haemostasis 1999; 82: 610–619.
   PubMed Web of Science ®Google Scholar
• Perrier A. Deep vein thrombosis and pulmonary embolism: a single disease entity with different risk factors? Chest 2000; 118: 1234–1236.
   PubMed Web of Science ®Google Scholar
• Bates SM, Hirsh J. Treatment of venous thromboembolism. Thrombosis and Haemostasis 1999; 82: 870–877.
   PubMed Web of Science ®Google Scholar
• Hirsh J. Low-molecular-weight heparin for the treatment of venous thromboembolism. American Heart Journal 1998; 135: S336–S342.
   Web of Science ®Google Scholar
• Simonneau G, Charbonnier B, Decousus H et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine 1993; 153: 1541–1546.
   PubMed Web of Science ®Google Scholar
• Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine 1992; 326: 975–982.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Buller HR et al. Comparison of subcutaneous low- molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441–445.
   PubMed Web of Science ®Google Scholar
• Merli G, Spiro TE, Olsson CG et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine 2001; 134: 191–202.
   PubMed Web of Science ®Google Scholar
• Dolovich LR, Ginsberg JS, Douketis JD et al. A meta-analysis comparing low- molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Archives of Internal Medicine 2000; 160: 181–188.
   PubMed Web of Science ®Google Scholar
• Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Archives of Internal Medicine 1995; 155: 601–607.
   PubMed Web of Science ®Google Scholar
• Levine M, Gent M, Hirsch J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine 1996; 334: 677–681.
   PubMed Web of Science ®Google Scholar
• Koopman MM, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low- molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine 1996; 334: 682–687.
   PubMed Web of Science ®Google Scholar
• Eikelboom J, Baker R. Routine home treatment of deep vein thrombosis. British Medical Journal 2001; 322: 1192–1193.
   PubMed Web of Science ®Google Scholar
• Kearon C, Gent M, O’Shaughnessy D et al. Heparin therapy for deep vein thrombosis: from hospital to home. American Journal of Medicine 2001; 110: 501-502. Hull RD, Raskob GE, Brant RF et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Archives of Internal Medicine 2000; 160: 229–236.
   Google Scholar
• Kovacs J. Outpatient treatment of pulmonary embolism with dalteparin. Thrombosis and Haemostasis 2000; 83: 209–211.
   Google Scholar
• Wells PS, Kovacs MJ, Bormanis J et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular- weight heparin: a comparison of patient self-injection with homecare injection. Archives of Internal Medicine 1998; 158: 1809–1812.
   PubMedGoogle Scholar
• Simonneau G. New perspectives for treatment of pulmonary embolism. Haemostasis 1998; 28 (Suppl. 3): 95–99.
   PubMedGoogle Scholar
• Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Archives of Internal Medicine 2000; 160: 2926–2932.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1–17.
   PubMed Web of Science ®Google Scholar
• Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Seminars in Thrombosis and Hemostasis 2000; 26 (Suppl. 1): 31–38.
   Google Scholar
• Collignon F, Frydman A, Caplain H et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins – dalteparin, enoxaparin and nadroparin – administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thrombosis and Haemostasis 1995; 73: 630–640.
   PubMed Web of Science ®Google Scholar
• Summary of Main Product Characteristics: Clexane®, 2001. Aventis Pharmaceuticals, West Malling, UK.
   Google Scholar
• British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary, 42. The Pharmaceutical Press, 2001.
   Google Scholar
• Fox KA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. British Journal of Cardiology 1998; 5: 92–105.
   Google Scholar
• Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular- weight heparin: outcome of therapy and health economy aspects. Haemostasis 1998; 28 (Suppl. 3): 8–16.
   Google Scholar
• Netten A, Dennet J, Knight J. Unit Costs of Health and Social Care. PSSRU Canterbury, 2000.
   Google Scholar
• van den Belt AG, Bossuyt PM, Prins MH et al. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis – an economic evaluation. TASMAN Study Group. Thrombosis and Haemostasis 1998; 79: 259–263.
   PubMed Web of Science ®Google Scholar
• Pearson SD, Blair R, Halpert A et al. An outpatient program to treat deep venous thrombosis with low-molecular- weight heparin. Effective Clinical Practice 1999; 2: 210–217.
   PubMedGoogle Scholar
• Deitcher SR, Olin JW, Bartholomew J. How to use low-molecular weight heparin for outpatient management of deep vein thrombosis. Cleveland Clinical Journal of Medicine 1999; 66: 329–331.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy DF, Tovey C, Miller AL et al. Outpatient management of deep vein thrombosis. Journal of Accident and Emergency Medicine 1998; 15: 292–293.
   PubMedGoogle Scholar
• O’Shaughnessy D, Miles J, Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. Quarterly Journal of Medicine 1993; 93: 663–667.
   Google Scholar
• Vinson DR, Berman DA. Outpatient treatment of deep venous thrombosis: a clinical care pathway managed by the emergency department. Annals of Emergency Medicine 2001; 37: 251–258.
   PubMed Web of Science ®Google Scholar
• Grau E, Tenias JM, Real E et al. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. American Journal of Hematology 2001; 67: 10–14.
   PubMed Web of Science ®Google Scholar
• Blattler W, Kreis N, Blattler IK. Practicability and quality of outpatient management of acute deep venous thrombosis. Journal of Vascular Surgery 2000; 32: 855–860.
   PubMed Web of Science ®Google Scholar
• Gilbert KB, Rodgers GM. Utilization and outcomes of enoxaparin treatment for deep-vein thrombosis in a tertiary-care hospital. American Journal of Hematology 2000; 65: 285–288.
   PubMed Web of Science ®Google Scholar
• Sanderink GJ et al. Enoxaparin pharmacokinetics and pharmacodynamics in obese subjects. Journal of the American College of Cardiology 2001; 37: 229A.
   Web of Science ®Google Scholar
• Sanderink GJ et al. Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment. Journal of the American College of Cardiology 2001; 37: 229A.
   Web of Science ®Google Scholar
• Harvey DM, Offord RH. Management of venous and cardiovascular thrombosis: enoxaparin. Hospital Medicine 2000; 61: 628–636.
   PubMed Web of Science ®Google Scholar